Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: Results of arm II of Radiation Therapy Oncology Group (RTOG) 0116

International Journal of Gynecological Cancer

Volumn 21, Issue 7, 2011, Pages 1266-1275

  Small Jr , William ^a   Winter, Kathryn ^b   Levenback, Charles ^c   Iyer, Revathy ^c   Hymes, Sharon R ^c   Jhingran, Anuja ^c   Gaffney, David ^d   Erickson, Beth ^e   Greven, Kathy ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RTOG Statistical Center   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f WAKE FOREST UNIVERSITY   (United States)

Author keywords

Amifostine; Cervical cancer; Chemoradiation; Extended field radiotherapy; Toxicity

Indexed keywords

AMIFOSTINE; ANTIHISTAMINIC AGENT; CIMETIDINE; CISPLATIN; DEXAMETHASONE; FLUORODEOXYGLUCOSE; GLUCOCORTICOID; GRANISETRON; ONDANSETRON; PROCHLORPERAZINE; ANTINEOPLASTIC AGENT; RADIOPROTECTIVE AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPETITE DISORDER; ARTICLE; BLADDER DISEASE; BLEEDING; BLOOD DISEASE; BONE DISEASE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMMON ILIAC LYMPH NODE METASTASIS; DEHYDRATION; DERMATITIS; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM DISEASE; ENDOCRINE DISEASE; ERYTHEMA MULTIFORME; EXFOLIATIVE DERMATITIS; EXTENDED FIELD IRRADIATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HUMAN; HYDRONEPHROSIS; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; INJECTION SITE RASH; INJECTION SITE SWELLING; INTRACAVITARY BRACHYTHERAPY; KIDNEY DISEASE; LARGE INTESTINE DISEASE; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DISEASE; LOCAL SKIN REACTION; LOW BACK PAIN; LUNG DISEASE; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OTOTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PARA AORTIC LYMPH NODE METASTASIS; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RASH; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT INDICATION; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; VISUAL IMPAIRMENT; WEIGHT REDUCTION; CARCINOMA; CLINICAL TRIAL; MIDDLE AGED; RADIATION INJURY; UTERINE CERVIX TUMOR;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA; CISPLATIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; UTERINE CERVICAL NEOPLASMS;

EID: 84856072804     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31822c2769     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
3. National Cancer Institute. Clinical announcement - direct mailing: concurrent chemoirradiation for cervical cancer. February 1999; 1-5.
4. Lovecchio JL, Averette HE, Donato D, et al. 5-year survival of patients with periaortic nodal metastases in clinical stage IB and II cervical carcinoma. Gynecol Oncol. 1989;34:43-45. (Pubitemid 19187959)
5. Maltefano JH, Keys H. Aggressive multimodality treatment for cervical cancer with paraaortic lymph nodes metastases. Gynecol Oncol. 1991;42:44-47.
6. Varia MA, Bundy BN, Deppe G, et al. Cervical carcinoma metastatic to para-aortic nodes: extended-field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998;42:1015-1023. (Pubitemid 29004143)
7. Grigsby PW, Heydon K, Mutch DG, et al. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001;51:982-987. (Pubitemid 33026428)
8. Small W Jr, Winter K, Levenback C, et al. Extended field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007;68:1081-1087. (Pubitemid 47048563)
9. Sasse AD, Clark LG, Sasse EC, et al. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys. 2006;64:784-791. (Pubitemid 43183575)
10. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 1999;26:3-21. (Pubitemid 29246624)
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat. 1958;53:457-481.
12. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980:167-169.
13. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101-2112. (Pubitemid 26230113)
14. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345.
15. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol. 2000;18:2226-2233. (Pubitemid 30350214)
16. Anné PR, Machtay M, Rosenthal DI, et al. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2007;67:445-452. (Pubitemid 46108306)
17. Wadler S, Beitler JJ, Rubin JS, et al. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group Study. J Clin Oncol. 1993;11:1511-1516. (Pubitemid 23228256)
18. Runowicz CD, Wadler S, Rodriguez-Rodriguez L, et al. Concomitant cisplatin and radiotherapy in locally advanced cervical cancer. Gynecol Oncol. 1989;34:395-401.
19. Gallardo D, Mohar A, Calderillo G, et al. Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix. Int J Gynecol Cancer. 1999;9:225-230. (Pubitemid 29302858)
20. Athanassiou H, Antonadou D, Coliarakis N, et al. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2003;15:1154-1160. (Pubitemid 36794050)